"Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust developmen ...

The oral presentations ... Abstract Title: Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data Date and Time: Wednesday, March 19, at 12:30-12:45 p.m. CT Poster ...

Implantica reported a mixed financial performance for Q4 2024, with a 30% year-over-year decrease in quarterly revenue to €442,000, while full-year net sales rose by 38% to €1.9 million. The company's ...

Background: Most patients diagnosed with small cell lung cancer have extensive stage disease (ES-SCLC) at presentation, portending a poor ... RT would improve the PFS from 5 months to 8 months. sample ...

Background: The efficacy and safety of neoadjuvant immunotherapy (NAI) for treating resectable locally advanced head and neck squamous cell carcinoma (LAHNSCC) remain uncertain, and the comprehensive ...

Describe your research experiences and skills (for example, your specific roles in research projects, peer-reviewed publications, oral/poster presentations, or other research-related experiences).

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.